A clinically integrated translational science programme to progress positive biomarker and therapeutics development for forms of breast cancer currently defined as Triple Negative

Project: Research

Project Details

StatusFinished
Effective start/end date15/10/201331/10/2022

Collaborative partners

Funding

  • Breakthrough Breast Cancer: £850,000.00
  • Breakthrough Breast Cancer: £417,073.88
  • Breast Cancer Now: £850,000.00
  • Breakthrough Breast Cancer: £699,999.00
  • Breakthrough Breast Cancer: £700,000.00
  • Breakthrough Breast Cancer: £800,000.00